Cue Biopharma (CUE) Non-Current Deffered Revenue (2017 - 2018)
Cue Biopharma (CUE) posted Non-Current Deffered Revenue of $9000.0 for Q1 2018, down 75.0% sequentially from $36000.0 in Q4 2017.
Cue Biopharma (CUE) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Cue Biopharma has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $9000.0 in Q1 2018.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $9000.0 in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $9000.0 (changed N/A YoY) and the FY2017 annual result came in at $36000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue slipped to $9000.0 in Q1 2018 per CUE's latest filing, from $36000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $36000.0 in Q4 2017 and troughed at $9000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 9,000.00 |
| Dec 31, 2017 | 36,000.00 |